Using a new model dubbed DEMETER2, the Ó³»´«Ã½'s Cancer Dependency Map team has compiled the largest dataset of genetic dependencies in cancer to date.
John Doench, associate director of the Genetic Perturbation Platform (GPP) and institute scientist at the Ó³»´«Ã½, and Ruth Hanna, research associate in GPP, discuss how the CRISPR system has revolutionized studies of gene function.
Cancer cells thrive despite harboring mutations that should kill them. By mapping the dependencies cancer cells rely on for survival, researchers hope to reveal new treatment opportunities.